Garetosmab

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Weight LossFibrodysplasia Ossificans Progressiva

105 competitors in Weight Loss

#DrugCompanyPhaseTrials

1

Megace

Bristol-Myers Squibb

Phase 3

102

Byetta

AstraZeneca

Phase 3

33

Mounjaro

Eli Lilly

Phase 3

14

Revia

Teva

Phase 3

15

Glucophage

EMD Serono

Phase 3

86

Meridia

AAbbott

Phase 3

77

Botox

RRevance Therapeutics, Inc.

Phase 3

18

Cagrilintide

Novo Nordisk

Phase 3

19

Rimonabant

Sanofi

Phase 3

110

Byetta

Bristol-Myers Squibb

Phase 3

1Show 38 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Fibrodysplasia Ossificans Progressiva3 trials

An Expanded Access Program of Garetosmab in Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP)

Temporarily not available·Regeneron··NCT07301450

A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)

Active, not recruiting·Regeneron·Phase 3·NCT05394116·63 enrolled

Study to Assess the Efficacy and Safety of Garetosmab in Japanese Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP)

Withdrawn·Regeneron·Phase 3·NCT04577820

Weight loss1 trial

A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation

Active, not recruiting·Regeneron·Phase 2·NCT06299098·1,005 enrolled

Menopausal Women1 trial

Study of Safety and Effects of Garetosmab in Healthy Obese Men and Post-Menopausal Women

Withdrawn·Regeneron·Phase 1·NCT06970405

Details

Drug Info

Related News